Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
BradsaudeBSP:SAUD3 -1.15%94 3-Year EBITDA Growth Rate is 26.70% as of Jun. 2026, which is 83% above its 10-year median of 14.60. GuruFocus rates BSP:SAUD3 with a GF Score™ of 94/100 and a GF Value™ of R$18.26 (Modestly Undervalued). The stock has 5 warning signs investors should review. Among 16 Healthcare Plans companies, Bradsaude ranks better than 75% on this metric.
During the past 12 months, Bradsaude's average EBITDA Per Share Growth Rate was -0.40% per year.
During the past 3 years, the average EBITDA Per Share Growth Rate was 26.70% per year.
During the past 5 years, the average EBITDA Per Share Growth Rate was 21.40% per year.
During the past 10 years, the average EBITDA Per Share Growth Rate was 15.40% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
During the past 13 years, the highest 3-Year average EBITDA Per Share Growth Rate of Bradsaude was 35.20% per year. The lowest was -2.80% per year. And the median was 14.60% per year.
EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.
Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.
Bradsaude 3-Year EBITDA Growth Rate Related Terms
BSP:SAUD3 vs UNH, CVS, ELV: 3-Year EBITDA Growth Rate Comparison
For the Healthcare Plans subindustry, Bradsaude's 3-Year EBITDA Growth Rate, along with its competitors' market caps and 3-Year EBITDA Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Bradsaude 3-Year EBITDA Growth Rate vs Healthcare Plans Industry
For the Healthcare Plans industry and Healthcare sector, Bradsaude's 3-Year EBITDA Growth Rate distribution charts can be found below:
* The bar in red indicates where Bradsaude's 3-Year EBITDA Growth Rate falls into.
This is the 3-year average growth rate of EBITDA per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
What does a 3-Year EBITDA Growth Rate of 26.70% mean?
Bradsaude (BSP:SAUD3) has a 3-Year EBITDA Growth Rate of 26.70% as of Jun. 2026. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Bradsaude and its competitors. This is 83% above median its historical median of 14.60. According to the industry distribution chart, Bradsaude ranks #4 out of 16 companies in the Healthcare Plans industry, placing it in the top 25%.
Is Bradsaude's 3-Year EBITDA Growth Rate too high?
Bradsaude's current 3-Year EBITDA Growth Rate of 26.70% is 83% above median its 10-year median of 14.60. Based on the distribution chart, Bradsaude ranks #4 out of 16 companies in the Healthcare Plans industry, which is in the top quartile — a strong position relative to peers. Overall, Bradsaude has a GF Score™ of 94/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Bradsaude's 3-Year EBITDA Growth Rate compare to UNH and CVS?
According to the Healthcare Plans industry distribution chart, Bradsaude ranks #4 out of 16 companies for 3-Year EBITDA Growth Rate. This places Bradsaude in the top 25% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year EBITDA Growth Rate for a Healthcare Plans company?
A good 3-Year EBITDA Growth Rate depends on the Healthcare Plans industry context. However, 3-Year EBITDA Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year EBITDA Growth Rate mean?
A high 3-Year EBITDA Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Bradsaude and its competitors. Bradsaude's current 3-Year EBITDA Growth Rate is 26.70%, which is 83% above median its own 10-year median of 14.60. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Bradsaude stock overvalued right now?
Based on GuruFocus' analysis, Bradsaude (BSP:SAUD3) is currently considered Modestly Undervalued. The stock's GF Value™ is R$18.26, compared to a current price of R$13.72 — trading 24.9% below its estimated fair value. The current 3-Year EBITDA Growth Rate is 26.70%, which is 83% above median its 10-year median of 14.60. Bradsaude's overall GF Score™ is 94/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year EBITDA Growth Rate calculated?
3-Year EBITDA Growth Rate is calculated from a company's financial statements. For Bradsaude (BSP:SAUD3), the current 3-Year EBITDA Growth Rate is 26.70% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Bradsaude (BSP:SAUD3) Overvalued in 2026?
Based on GuruFocus' analysis, Bradsaude stock appears to be undervalued.
The current stock price of R$13.72 is trading 24.9% below its estimated GF Value™ of R$18.26.
GuruFocus considers Bradsaude to be Modestly Undervalued.
Key valuation signals for BSP:SAUD3:
3-Year EBITDA Growth Rate: 26.70% (83% above median its 10-year median of 14.60)
GF Value™: R$18.26 vs. price of R$13.72 (24.9% below fair value)
No single metric tells the full story. See the BSP:SAUD3 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Bradsaude SA operates a healthcare ecosystem in Brazil formed through the consolidation of companies across different healthcare segments. Its operations include health and dental insurance, hospitals, primary care clinics, healthcare technology, diagnostics, and oncology services. The company serves more than 13 million beneficiaries and operates a healthcare network that includes approximately 4,000 hospital beds across the country.
94GF Score
Get the complete analysis for BSP:SAUD3
3-Year EBITDA Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BSP:SAUD3 has been successfully added to your 
